questionsmedicales.fr
États, signes et symptômes pathologiques
Signes et symptômes
Signes et symptômes respiratoires
Hyperventilation
Hyperventilation : Questions médicales fréquentes
Termes MeSH sélectionnés :
Angiotensin Receptor Antagonists
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperventilation : Questions médicales les plus fréquentes",
"headline": "Hyperventilation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperventilation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-06",
"dateModified": "2025-03-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperventilation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Signes et symptômes respiratoires",
"url": "https://questionsmedicales.fr/mesh/D012818",
"about": {
"@type": "MedicalCondition",
"name": "Signes et symptômes respiratoires",
"code": {
"@type": "MedicalCode",
"code": "D012818",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.852"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hyperventilation",
"alternateName": "Hyperventilation",
"code": {
"@type": "MedicalCode",
"code": "D006985",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Naoto Fujii",
"url": "https://questionsmedicales.fr/author/Naoto%20Fujii",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Health and Sport Sciences, University of Tsukuba , Tsukuba , Japan."
}
},
{
"@type": "Person",
"name": "Takeshi Nishiyasu",
"url": "https://questionsmedicales.fr/author/Takeshi%20Nishiyasu",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Health and Sport Sciences, University of Tsukuba , Tsukuba , Japan."
}
},
{
"@type": "Person",
"name": "Eun Hye Oh",
"url": "https://questionsmedicales.fr/author/Eun%20Hye%20Oh",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea."
}
},
{
"@type": "Person",
"name": "Seo Young Choi",
"url": "https://questionsmedicales.fr/author/Seo%20Young%20Choi",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea."
}
},
{
"@type": "Person",
"name": "Thomas Ritz",
"url": "https://questionsmedicales.fr/author/Thomas%20Ritz",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37231800",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530988"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36682353",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000528783"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37421275",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.122.028865"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort.",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/37016775",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.32725/jab.2023.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction.",
"datePublished": "2023-03-09",
"url": "https://questionsmedicales.fr/article/36893150",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0281460"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Signes et symptômes respiratoires",
"item": "https://questionsmedicales.fr/mesh/D012818"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hyperventilation",
"item": "https://questionsmedicales.fr/mesh/D006985"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperventilation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperventilation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperventilation",
"description": "Comment diagnostiquer l'hyperventilation ?\nQuels tests sont utilisés pour l'hyperventilation ?\nL'hyperventilation peut-elle être confondue avec d'autres conditions ?\nQuels signes cliniques indiquent l'hyperventilation ?\nL'hyperventilation est-elle mesurable ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperventilation",
"description": "Quels sont les symptômes courants de l'hyperventilation ?\nL'hyperventilation provoque-t-elle des douleurs thoraciques ?\nPeut-on ressentir de l'anxiété avec l'hyperventilation ?\nL'hyperventilation entraîne-t-elle une fatigue ?\nLes symptômes de l'hyperventilation sont-ils permanents ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperventilation",
"description": "Comment prévenir l'hyperventilation ?\nLes exercices de respiration aident-ils à prévenir l'hyperventilation ?\nL'éducation sur l'anxiété peut-elle prévenir l'hyperventilation ?\nLe yoga peut-il aider à prévenir l'hyperventilation ?\nLes techniques de méditation sont-elles utiles ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperventilation",
"description": "Quels traitements sont disponibles pour l'hyperventilation ?\nComment la thérapie comportementale aide-t-elle ?\nLes médicaments sont-ils nécessaires pour l'hyperventilation ?\nQuelles techniques de respiration sont recommandées ?\nL'hyperventilation nécessite-t-elle une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperventilation",
"description": "Quelles complications peuvent survenir avec l'hyperventilation ?\nL'hyperventilation peut-elle causer des évanouissements ?\nDes troubles cardiaques peuvent-ils être liés à l'hyperventilation ?\nL'hyperventilation peut-elle affecter la santé mentale ?\nY a-t-il des risques à long terme liés à l'hyperventilation ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperventilation",
"description": "Quels sont les facteurs de risque de l'hyperventilation ?\nL'anxiété est-elle un facteur de risque ?\nLes athlètes sont-ils plus à risque d'hyperventilation ?\nLes maladies pulmonaires augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperventilation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes respiratoires."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'hyperventilation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de gaz du sang peuvent être effectués pour évaluer les niveaux de CO2."
}
},
{
"@type": "Question",
"name": "L'hyperventilation peut-elle être confondue avec d'autres conditions ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec l'anxiété ou des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent l'hyperventilation ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des palpitations, des étourdissements et des picotements peuvent indiquer l'hyperventilation."
}
},
{
"@type": "Question",
"name": "L'hyperventilation est-elle mesurable ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être mesurée par la fréquence respiratoire et les niveaux de CO2 dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hyperventilation ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des palpitations, et des sensations de picotement."
}
},
{
"@type": "Question",
"name": "L'hyperventilation provoque-t-elle des douleurs thoraciques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des douleurs thoraciques dues à une tension musculaire."
}
},
{
"@type": "Question",
"name": "Peut-on ressentir de l'anxiété avec l'hyperventilation ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hyperventilation peut être à la fois un symptôme et un déclencheur d'anxiété."
}
},
{
"@type": "Question",
"name": "L'hyperventilation entraîne-t-elle une fatigue ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut survenir en raison d'une respiration inefficace et d'une hyperoxie."
}
},
{
"@type": "Question",
"name": "Les symptômes de l'hyperventilation sont-ils permanents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont généralement temporaires et liés à des épisodes de stress ou d'anxiété."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperventilation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par la gestion du stress, des techniques de relaxation et une respiration consciente."
}
},
{
"@type": "Question",
"name": "Les exercices de respiration aident-ils à prévenir l'hyperventilation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des exercices réguliers de respiration peuvent aider à stabiliser le rythme respiratoire."
}
},
{
"@type": "Question",
"name": "L'éducation sur l'anxiété peut-elle prévenir l'hyperventilation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre l'anxiété et ses effets peut réduire les épisodes d'hyperventilation."
}
},
{
"@type": "Question",
"name": "Le yoga peut-il aider à prévenir l'hyperventilation ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le yoga favorise la relaxation et améliore la conscience respiratoire."
}
},
{
"@type": "Question",
"name": "Les techniques de méditation sont-elles utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la méditation aide à réduire le stress et à réguler la respiration."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hyperventilation ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des techniques de respiration, la thérapie cognitivo-comportementale et des médicaments."
}
},
{
"@type": "Question",
"name": "Comment la thérapie comportementale aide-t-elle ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle aide à gérer l'anxiété et à modifier les comportements de respiration inappropriés."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils nécessaires pour l'hyperventilation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, mais des anxiolytiques peuvent être prescrits si l'anxiété est sévère."
}
},
{
"@type": "Question",
"name": "Quelles techniques de respiration sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la respiration diaphragmatique et la respiration lente sont recommandées."
}
},
{
"@type": "Question",
"name": "L'hyperventilation nécessite-t-elle une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, sauf en cas de complications graves ou de crises d'anxiété sévères."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hyperventilation ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles électrolytiques, des spasmes musculaires et des évanouissements."
}
},
{
"@type": "Question",
"name": "L'hyperventilation peut-elle causer des évanouissements ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperventilation sévère peut entraîner des évanouissements en raison d'une hypoxie."
}
},
{
"@type": "Question",
"name": "Des troubles cardiaques peuvent-ils être liés à l'hyperventilation ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hyperventilation peut provoquer des palpitations et des douleurs thoraciques, mais rarement des troubles cardiaques graves."
}
},
{
"@type": "Question",
"name": "L'hyperventilation peut-elle affecter la santé mentale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut exacerber l'anxiété et mener à des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques à long terme liés à l'hyperventilation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques à long terme incluent des problèmes respiratoires chroniques et des troubles anxieux."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hyperventilation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le stress, l'anxiété, les troubles respiratoires et certaines conditions médicales."
}
},
{
"@type": "Question",
"name": "L'anxiété est-elle un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'anxiété est un facteur majeur qui peut déclencher des épisodes d'hyperventilation."
}
},
{
"@type": "Question",
"name": "Les athlètes sont-ils plus à risque d'hyperventilation ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les athlètes peuvent hyperventiler lors d'efforts intenses ou de stress compétitif."
}
},
{
"@type": "Question",
"name": "Les maladies pulmonaires augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme l'asthme ou la BPCO peuvent augmenter le risque d'hyperventilation."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les problèmes respiratoires et augmenter le risque d'hyperventilation."
}
}
]
}
]
}
Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are frequently discontinued in patients with chronic kidney disease (CKD). Documented adverse drug reactions (...
In this retrospective cohort of US veterans from 2005 to 2019, we identified individuals with CKD and a current prescription for an ACEi or ARB (current user group) or a discontinued prescription with...
There were 882,441 (73.0%) individuals in the current user group and 326,794 (27.0%) in the discontinued group. There were 26,434 documented ADRs, with at least one documented ADR in 7,520 (0.9%) curr...
ADRs leading to drug discontinuation were infrequently documented. ADR types were differentially associated with treatment discontinuation. An understanding of which ADRs lead to treatment discontinua...
Diabetic kidney disease (DKD) is a common disorder with multiple serious clinical implications, including an increased risk of end-stage kidney disease (ESKD), cardiovascular complications, heart fail...
Upregulation of the renin-angiotensin-aldosterone system is an important contributor to kidney disease progression, as highlighted by the results of trials evaluating angiotensin-converting enzyme inh...
Aldosterone can promote kidney disease in diabetes via the MR and via MR-independent actions through Rac1. However, the MR remains a key element of this triangle, with clinical data supporting the use...
Background PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of sacu...
Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to be effective in managing cardiovascular diseases, but more evidence supports the use of a...
Patients who were first prescribed ACEIs or ARBs at two tertiary university hospitals in Korea were observed in this retrospective cohort study for the incidence of heart failure, angina, acute myocar...
Overall, 2,945 and 9,189 patients were prescribed ACEIs and ARBs, respectively. When compared to ACEIs, the incidence of heart failure decreased by 52% in those taking ARBs (HR [95% CI] = 0.48 [0.39-0...
ARBs were not inferior to ACEIs in relation to reducing the incidence of cardiocerebrovascular disease in the clinical setting; however, there were slight differences for each disease. The greatest st...
There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-c...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global prevalence of diabetes mellitus and hypertension. While renin angiotensin system inhibitors and sodiu...
Chronic kidney disease (CKD) is a long-term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated ...
To evaluate the benefits and harms of ACEi and ARB or both in the management of people with early (stage 1 to 3) CKD who do not have diabetes mellitus (DM)....
We searched the Cochrane Kidney and Transplant Register of Studies up to 6 July 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register...
Randomised controlled trials (RCTs) reporting the effect of ACEi or ARB in people with early (stage 1 to 3) CKD who did not have DM were selected for inclusion. Only studies of at least four weeks dur...
Data extraction was carried out by two authors independently, using a standard data extraction form. The methodological quality of included studies was assessed using the Cochrane risk of bias tool. D...
There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and...
Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 bloc...
We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated with immune checkpoint inhibitors (ICIs) across all types of cance...
A total of 167 patients receiving both angiotensin receptor blockers (ARBs) and immune checkpoint inhibitors (ICIs) were included. Compared with non-PPAR-γ-ARB users (n = 102), PPAR-γ-ARB users (n = 6...
The use of ARBs with PPAR-γ-activating property is linked with better survival among patients receiving ICIs....
We investigated the effect of angiotensin receptor neprilysin inhibitor (ARNI) on glycemic control in Korean patients. This retrospective cohort study was conducted at a single tertiary hospital. We c...
The present study evaluated the clinical results of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment in patients with unstable angina (UA) with preserved ...